Synergistic effect of CGS16949A and 5-fluorouracil on a human breast cancer cell line.
The effects of the aromatase inhibitor, CGS16949A, and the fluoropyrimidine, 5-fluorouracil (5-FU), on cell cycle distribution and growth were studied using FACS analysis and MTT assay in the human breast cancer cell line, SK-BR-3. CGS16949A induced an increase in the G0-G1 fraction on SK-BR-3 cells, and the growth inhibition rate of the combination of both (65.7 +/- 3.0%) was significantly higher than 10 nM CGS16949A (37.9 +/- 6.9%) or 100 microg/ml 5-FU (45.6 +/- 4.5%); p < 0.01). Administering 5-FU after preincubation with CGS16949A significantly increased the combined cytotoxic efficacy, suggesting that clinical therapy using this combined therapy may be more efficient.
Tsunoda
Y
Y
Second Department of Surgery, Showa University School of Medicine, Tokyo, Japan.
Shimizu
Y
Y
Tsunoda
A
A
Shibusawa
M
M
Kamiya
K
K
Kusano
M
M
Fukuchi
K
K
D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology*; D001141:Aromatase / Q000378:metabolism*; D001943:Breast Neoplasms / Q000201:enzymology* / Q000473:pathology*; D002453:Cell Cycle / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D017316:Fadrozole / Q000494:pharmacology*; D005260:Female; D005472:Fluorouracil / Q000494:pharmacology*; D006801:Humans; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000964:Antimetabolites, Antineoplastic; D018931:Antineoplastic Agents, Hormonal; D001141:Aromatase; D017316:Fadrozole; D005472:Fluorouracil